Envu reports psoriasis and lupus trial efficacy; NDA on track
Envu says it demonstrated strong efficacy and safety in psoriasis and promising results in biomarker-positive lupus, and that its NDA filing remains on track for Q4.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.